Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB/Flu-05E Intranasal Vaccine Phase 1
NCT05945498Phase 1Completed
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Tuberculosis (TB) comparing TB/Flu-05E vaccine with Placebo (2 arms). Primary endpoint: Number of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs) at 4 months. Started May 2023; status: completed.
02
Drugs
TB/Flu-05E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05945498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945498.